A dual-targeting near-infrared biomimetic drug delivery system for HBV treatment

作者全名："Chen, Liuxian; Jiang, Xinyun; Liu, Qiang; Tang, Zhenrong; Wang, Dan; Xiang, Zheng; Liu, Shengchun; Tang, Hua"

作者地址："[Chen, Liuxian; Jiang, Xinyun; Tang, Hua] Chongqing Med Univ, Key Lab Mol Biol Infect Dis, Minist Educ, Chongqing 400016, Peoples R China; [Liu, Qiang; Xiang, Zheng] Chongqing Med Univ, Dept Gastrointestinal Surg, Affiliated Hosp 1, Chongqing, Peoples R China; [Tang, Zhenrong; Liu, Shengchun] Chongqing Med Univ, Dept Endocrine & Breast Surg, Affiliated Hosp 1, Chongqing, Peoples R China; [Wang, Dan] Peoples Hosp Rongchang Dist, Chongqing, Peoples R China"

通信作者："Tang, H (通讯作者)，Chongqing Med Univ, Key Lab Mol Biol Infect Dis, Minist Educ, Chongqing 400016, Peoples R China."

来源：JOURNAL OF MEDICAL VIROLOGY

ESI学科分类：MICROBIOLOGY

WOS号：WOS:000911465200232

JCR分区：Q1

影响因子：6.8

年份：2023

卷号：95

期号：1

开始页：　

结束页：　

文献类型：Article

关键词：cell membranes; HBV synergistic therapy; liver cell targeting delivery; photoinduced release; upconversion nanoparticles

摘要："Hepatitis B virus (HBV) infection is a serious global public health threat. It remains elusive to achieve a functional HBV cure with currently available antivirals. Herein, a photo-responsive delivery vehicle composed of Nd3+-sensitized core-shell upconversion nanoparticle (UCNP), mesoporous silica nanoparticle (MSN), antisense oligonucleotides (ASOs), and capsid-binding inhibitor C39 was established, which was named UMAC according to the initials of its components. Subsequently, the as-synthesized delivery vehicle was encapsulated by beta-D-galactopyranoside (Gal) modified red blood cell (RBC) membrane vesicles, which enabled precise targeting of the liver cells (UMAC-M-Gal). Both in vitro and in vivo experiments demonstrated that this biomimetic system could successfully achieve controlled drug release under light conditions at 808 nm, leading to effective suppression of HBV replication in this dual-targeted therapeutic approach. Together, these results substantiate the system has huge prospects for application to achieve functional HBV cure, and provides a promising novel strategy for drug delivery."

基金机构："Key Laboratory of Infectious Diseases, CQMU"

基金资助正文："Key Laboratory of Infectious Diseases, CQMU"